Otomycosis: The foremost aetiological agent causing otitis externa and the antifungal susceptibility pattern in North-Western Iran.
Aspergillus section Nigri
Iran
molecular identification
otitis externa
otomycosis
susceptibility testing
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
revised:
01
09
2022
received:
15
07
2022
accepted:
15
09
2022
pubmed:
23
9
2022
medline:
12
1
2023
entrez:
22
9
2022
Statut:
ppublish
Résumé
Otomycosis is considered a recurring fungal ear infection. The external auditory canal provides an appropriate and optimal situation for fungal growth. The study aimed to identify the causative agents of otomycosis and determine corresponding antifungal drug susceptibility patterns in north-western Iran. From October 2020 until November 2021, 200 patients attended an otolaryngology referral centre with otitis externa, and their ear discharge and debris were examined and cultured. The identification of the fungal agents was implemented by polymerase chain reaction-restriction fragment length polymorphism and sequencing. In vitro antifungal susceptibility testing of the isolates was conducted in accordance with the CLSI broth microdilution protocols. The prevalence of otomycosis was measured 50.5% (n = 101/200). The majority of patients were in their forties (n = 35, 34.6%) and female (n = 57, 56.4%), and the most prevalent symptom was otalgia (56.4%). The most underlying factor was remarked manipulation employing a cotton swab (65.3%). Regarding fungus, Aspergillus section Nigri (58.57%) was the foremost isolate, followed by Aspergillus section Flavi (19.23%) and Candida parapsilosis (14.96%). The predominance of Aspergillus isolates had minimal in vitro sensitivity to tioconazole and nystatin. Candida species represented higher geometric mean minimum inhibitory concentrations (MIC) against nystatin. The MIC of three Aspergillus species isolates shown above the epidemiologic cut-off values (ECV) against itraconazole. Otomycosis incidence surpassed in comparison with the previous study as the most common cause of otitis externa. The MIC distribution of Aspergillus species isolates against triazole antifungals is close to the defined ECVs and likely outrun it over time.
Sections du résumé
BACKGROUND
BACKGROUND
Otomycosis is considered a recurring fungal ear infection. The external auditory canal provides an appropriate and optimal situation for fungal growth.
OBJECTIVES
OBJECTIVE
The study aimed to identify the causative agents of otomycosis and determine corresponding antifungal drug susceptibility patterns in north-western Iran.
METHODS
METHODS
From October 2020 until November 2021, 200 patients attended an otolaryngology referral centre with otitis externa, and their ear discharge and debris were examined and cultured. The identification of the fungal agents was implemented by polymerase chain reaction-restriction fragment length polymorphism and sequencing. In vitro antifungal susceptibility testing of the isolates was conducted in accordance with the CLSI broth microdilution protocols.
RESULTS
RESULTS
The prevalence of otomycosis was measured 50.5% (n = 101/200). The majority of patients were in their forties (n = 35, 34.6%) and female (n = 57, 56.4%), and the most prevalent symptom was otalgia (56.4%). The most underlying factor was remarked manipulation employing a cotton swab (65.3%). Regarding fungus, Aspergillus section Nigri (58.57%) was the foremost isolate, followed by Aspergillus section Flavi (19.23%) and Candida parapsilosis (14.96%). The predominance of Aspergillus isolates had minimal in vitro sensitivity to tioconazole and nystatin. Candida species represented higher geometric mean minimum inhibitory concentrations (MIC) against nystatin. The MIC of three Aspergillus species isolates shown above the epidemiologic cut-off values (ECV) against itraconazole.
CONCLUSIONS
CONCLUSIONS
Otomycosis incidence surpassed in comparison with the previous study as the most common cause of otitis externa. The MIC distribution of Aspergillus species isolates against triazole antifungals is close to the defined ECVs and likely outrun it over time.
Substances chimiques
Antifungal Agents
0
Nystatin
1400-61-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
87-97Subventions
Organisme : Mazandaran University of Medical Sciences
Informations de copyright
© 2022 Wiley-VCH GmbH.
Références
Phillips P, Bryce G, Shepherd J, Mintz D. Invasive external otitis caused by aspergillus. Rev Infect Dis. 1990;12(2):277-281. doi:10.1093/clinids/12.2.277
Gharaghani M, Seifi Z, Mahmoudabadi AZ. Otomycosis in Iran: a review. Mycopathologia. 2015;179(5-6):415-424. doi:10.1007/s11046-015-9864-7
Mills R. Malignant otitis externa. Br Med J (Clin Res ed). 1986;292(6518):429.
Murphy KM. A review of techniques for the investigation of otitis externa and otitis media. Clin Tech Small Anim Pract. 2001;16(4):236-241. doi:10.1053/svms.2001.27601
August JR. Otitis externa. Vet Clin North Am Small Anim Pract. 1988;18(4):731-742. doi:10.1016/S0195-5616(88)50076-1
Yehia MM, Al-Habib HM, Shehab NM. Otomycosis: a common problem in North Iraq. J Laryngol Otol. 1990;104(5):387-389. doi:10.1017/S0022215100158529
Zaini F, Mahbod ASA, Emami M. Comprehensive Medical Mycology. 4th ed. Tehran University publications; 2013.
Yang CS, Heinsohn PA. Sampling and Analysis of Indoor Microorganisms. Wiley online Library; 2007. doi:10.1002/9780470112434.ch3
Wang MC, Liu CY, Shiao AS, Wang T. Ear problems in swimmers. J Chinese Med Assoc. 2005;68(8):347-352. doi:10.1016/S1726-4901(09)70174-1
Deguine C, Pulec JL. Otomycosis with pus. Ear Nose Throat J. 2002;81(7):428.
Kaieda S. Fungal infection in the otorinolaryngologic area. Nihon Rinsho. 2008;66(12):2290-2293.
Baumgartner BJ, Rakita RM, Backous DD. Scedosporium apiospermum otomycosis. Am J Otolaryngol. 2007;28(4):254-256. doi:10.1016/j.amjoto.2006.08.017
Karaarslan A, Arikan S, Ozcan M, Ozcan KM. In vitro activity of terbinafine and itraconazole against aspergillus species isolated from otomycosis. Mycoses. 2004;47(7):284-287. doi:10.1111/j.1439-0507.2004.00988.x
Abastabar M, Haghani I, Ahangarkani F, et al. Candida auris otomycosis in Iran and review of recent literature. Mycoses. 2019;62(2):101-105. doi:10.1111/myc.12886
Ait Ouzdi Z, Ahroui Y, Zemrani Y, et al. Epidemiology of otomycosis at the military hospital avicenne of marrakech (morocco). Pathol Lab Med. 2019;3(1):19. doi:10.11648/j.plm.20190301.14
Li Y, He L. Diagnosis and treatment of otomycosis in southern China. Mycoses. 2019;62(11):1064-1068. doi:10.1111/myc.12979
Taghizadeh Armaki M, Mahdavi Omran S, Kiakojuri K, et al. First fluconazole-resistant Candida auris isolated from fungal otitis in Iran. Curr Med Mycol. 2021;7(1):51-54. doi:10.18502/cmm.7.1.6243
Tasić-Otašević S, Golubović M, Đenić S, et al. Species distribution patterns and epidemiological characteristics of otomycosis in southeastern Serbia. J Mycol Méd. 2020;30(3):101011. doi:10.1016/j.mycmed.2020.101011
Agarwal P, Devi LS. Otomycosis in a rural community attending a tertiary care hospital: assessment of risk factors and identification of fungal and bacterial agents. J Clin Diagn Res. 2017;11(6):DC14-DC18. doi:10.7860/JCDR/2017/25865.10068
Mohammadi R, Mirhendi H, Rezaei-Matehkolaei A, et al. Molecular identification and distribution profile of Candida species isolated from Iranian patients. Med Mycol. 2013;51(6):657-663. doi:10.3109/13693786.2013.770603
Nasri T, Hedayati MT, Abastabar M, et al. PCR-RFLP on β-tubulin gene for rapid identification of the most clinically important species of aspergillus. J Microbiol Methods. 2015;117:144-147. doi:10.1016/j.mimet.2015.08.007
Didehdar M, Shokohi T, Khansarinejad B, et al. Characterization of clinically important dermatophytes in north of Iran using PCR-RFLP on ITS region. J Mycol Med. 2016;26(4):345-350. doi:10.1016/j.mycmed.2016.06.006
Arastehfar A, Fang W, Pan W, Liao W, Yan L, Boekhout T. Identification of nine cryptic species of Candida albicans, C. glabrata, and C. parapsilosis complexes using one-step multiplex PCR. BMC Infect Dis. 2018;18(1):480. doi:10.1186/s12879-018-3381-5
CLSI, ed. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 4th Ed. CLSI Standard M27. Wayne, PA; 2017.
CLSI M. Epidemiological cutoff values for antifungal susceptibility testing. 2nd ed. CLSI supplement M59. : Clin Lab Stand Inst. Published online 2020:1-34.
Lass-Flörl C. Susceptibility testing in aspergillus species complex. Clin Microbiol Infect. 2014;20(6):49-53. doi:10.1111/1469-0691.12514
Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN. Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida. J Clin Microbiol. 2011;49(11):3800-3804. doi:10.1128/JCM.05047-11
Nemati S, Hassanzadeh R, Khajeh Jahromi S, Delkhosh Nasrollah Abadi A. Otomycosis in the north of Iran: common pathogens and resistance to antifungal agents. Eur Arch Oto-Rhino-Laryngology. 2014;271(5):953-957. doi:10.1007/s00405-013-2486-0
Nnadi NE, Carter DA. Climate change and the emergence of fungal pathogens. Jabra-Rizk MA, ed. PLoS Pathog. 2021;17(4):e1009503. 10.1371/journal.ppat.1009503
Cheraghsahar S, Kazemi S, Birjandi M, et al. Otomycosis in Western Iran: clinical and mycological aspects. Arch Clin Infect Dis. 2017;12(2):e57287. doi:10.5812/archcid.57287
Bineshian F, Irajian G, Koochak-Alavi SK, Fredonian MR. A study on the frequency of fungal agents in otitis externa in Semnan. Iran J Pathol. 2006;1(4):141-144.
Kazemi A, Majidinia M, Jaafari A, Mousavi SAA, Mahmoudabadi AZ, Alikhah H. Etiologic agents of otomycosis in the North-Western area of Iran. Jundishapur J Microbiol. 2015;8(9):e21776. doi:10.5812/jjm.21776
Pradhan B, Tuladhar NR, Amatya RM. Prevalence of otomycosis in an outpatient department of otolaryngology in Tribhuvan university teaching hospital, Kathmandu, Nepal. Ann Otol Rhinol Laryngol. 2003;112(4):384-387. doi:10.1177/000348940311200416
Ali K, Hamed M, Hassan H, Esmail A, Sheneef A. Identification of fungal pathogens in Otomycosis and their drug sensitivity: our experience. Int Arch Otorhinolaryngol. 2018;22(04):400-403. doi:10.1055/s-0038-1626702
Fasunla J, Ibekwe T, Onakoya P. Otomycosis in western Nigeria. Mycoses. 2008;51(1):67-70. doi:10.1111/j.1439-0507.2007.01441.x
Aboutalebian S, Mahmoudi S, Mirhendi H, Okhovat A, Abtahi H, Chabavizadeh J. Molecular epidemiology of otomycosis in Isfahan revealed a large diversity in causative agents. J Med Microbiol. 2019;68(6):918-923. doi:10.1099/jmm.0.000985
Shokouhi T, Ahanjan M, Kasiri A. Bacteriological and mycological study of external otitis in-patients referred to ent clinic of boo Ali Sina hospital in sari in summer 1999. J Maz Univ Med Sci. 2001;11(32):1-10.
Fayemiwo SA, Ogunleye VO, Adeosun AA, Bakare RA. Prevalence of otomycosis in Ibadan: a review of laboratory reports. Afr J Med Med Sci. 2010;39:219-222. PMID: 22420052.
Aneja KR, Sharma C, Joshi R. Fungal infection of the ear: a common problem in the north eastern part of Haryana. Int J Pediatr Otorhinolaryngol. 2010;74(6):604-607. doi:10.1016/j.ijporl.2010.03.001
Abdelazeem M, Gamea A, Mubarak H, Elzawawy N. Epidemiology, causative agents, and risk factors affecting human otomycosis infections. Turkish J Med Sci. 2015;45(4):820-826. doi:10.3906/sag-1407-17
Ho T, Vrabec JT, Yoo D, Coker NJ. Otomycosis: clinical features and treatment implications. Otolaryngol Neck Surg. 2006;135(5):787-791. doi:10.1016/j.otohns.2006.07.008
Sabz G, Gharaghani M, Mirhendi H, et al. Clinical and microbial epidemiology of otomycosis in the city of Yasuj, Southwest Iran, revealing aspergillus tubingensis as the dominant causative agent. J Med Microbiol. 2019;68(4):585-590. doi:10.1099/jmm.0.000948
Saki N, Rafiei A, Nikakhlagh S, Amirrajab N, Saki S. Prevalence of otomycosis in Khouzestan Province, south-West Iran. J Laryngol Otol. 2013;127(1):25. doi:10.1017/S0022215112002277.44
Gülüstan F, Abakay MA, Demir E. Efficacy of topical isoconazole nitrate in the treatment of otomycosis. Am J Otolaryngol. 2021;42(4):102961. doi:10.1016/j.amjoto.2021.102961
Sykes JE, Nagle TM, White SD. Pyoderma, otitis externa, and otitis media. Canine and Feline Infectious Diseases. Elsevier; 2014:800-813. doi:10.1016/B978-1-4377-0795-3.00084-3
da Silva Pontes ZBV, Ferreira Silva AD, de Oliveira LE, et al. Otomycosis: a retrospective study. Braz J Otorhinolaryngol. 2009;75(3):367-370. doi:10.1016/S1808-8694(15)30653-4
Sangaré I, Amona FM, Ouedraogo RWL, Zida A, Ouedraogo MS. Otomycosis in Africa: epidemiology, diagnosis, and treatment. J Med Mycol. 2021;31(2):101-115. doi:10.1016/j.mycmed.2021.101115
Kiakojuri K, Mahdavi Omran S, Roodgari S, et al. Molecular identification and antifungal susceptibility of yeasts and molds isolated from patients with otomycosis. Mycopathologia. 2021;186(2):245-257. doi:10.1007/s11046-021-00537-1
Javidnia J, Ghotbi Z, Ghojoghi A, et al. Otomycosis in the south of Iran with a high prevalence of tympanic membrane perforation: a hospital-based study. Mycopathologia. 2022;187(2-3):225-233. doi:10.1007/s11046-022-00626-9
Jia X, Liang Q, Chi F, Cao W. Otomycosis in Shanghai: aetiology, clinical features and therapy. Mycoses. 2012;55(5):404-409. doi:10.1111/j.1439-0507.2011.02132.x
Ismail M t, Alkafri A, Ismail M. Otomycosis in Damascus, Syria: etiology and clinical features. Curr Med Mycol. 2017;3(3):27-30. doi:10.29252/cmm.3.3.27
Mofatteh MR, Fersheh MA, Nikoomanesh F, Namaei MH. Comparing the therapy of otomycosis using clotrimazole with iodine tincture: a clinical trial. Iran J Otorhinolaryngol. 2021;33(4):229-235. doi:10.22038/ijorl.2021.51647.2751
Lima-Neto RG, Beltrão EIC, Oliveira PC, Neves RP. Adherence of Candida albicans and Candida parapsilosis to epithelial cells correlates with fungal cell surface carbohydrates. Mycoses. 2011;54(1):23-29. doi:10.1111/j.1439-0507.2009.01757.x
Kiakojuri K, Rajabnia R, Mahdavi Omran S, Pournajaf A, Karami M, Taghizadeh AM. Role of clotrimazole in prevention of recurrent Otomycosis. Biomed Res Int. 2019;2019:1-6. doi:10.1155/2019/5269535
Jackman A, Ward R, April M, Bent J. Topical antibiotic induced otomycosis. Int J Pediatr Otorhinolaryngol. 2005;69(6):857-860. doi:10.1016/j.ijporl.2005.01.022
Mofatteh MR, Naseripour Yazdi Z, Yousefi M, Namaei MH. Comparison of the recovery rate of otomycosis using betadine and clotrimazole topical treatment. Braz J Otorhinolaryngol. 2018;84(4):404-409. doi:10.1016/j.bjorl.2017.04.004
Ozcan KM, Ozcan M, Karaarslan A, Karaarslan F. Otomycosis in Turkey: predisposing factors, aetiology and therapy. J Laryngol Otol. 2003;117(1):39-42. doi:10.1258/002221503321046621
Aboutalebian S, Ahmadikia K, Fakhim H, et al. Direct detection and identification of the most common bacteria and fungi causing otitis externa by a stepwise multiplex PCR. Front Cell Infect Microbiol. 2021;11(March):1-11. doi:10.3389/fcimb.2021.644060
Kulal B, Bhat KS, Meundi M, Kotigadde S. A microbiological study of otomycosis. Indian J Microbiol Res. 2017;4(1):118-125. doi:10.18231/2394-5478.2017.0025
Munguia R, Daniel SJ. Ototopical antifungals and otomycosis: a review. Int J Pediatr Otorhinolaryngol. 2008;72(4):453-459. doi:10.1016/j.ijporl.2007.12.005
Kamali Sarvestani H, Seifi A, Falahatinejad M, Mahmoudi S. Black aspergilli as causes of otomycosis in the era of molecular diagnostics, a mini-review. J Med Mycol. 2022;32(2):101240. doi:10.1016/j.mycmed.2021.101240